Skin SSG (Anglia East & Anglia West)
|
|
- Ursula Stevens
- 5 years ago
- Views:
Transcription
1 Guidelines for Referrals between Skin LMDT and SMDT Skin SSG (Anglia East & Anglia West) Author: Dr Jennifer Garioch, Consultant Dermatologist Dr Pamela Todd, Consultant Dermatologist Approved by: Anglia Cancer Network Skin NSSG Approved on: Reviewed and Re-issued with no changes on 11 th May 2011 Next review due: May 2013 Ref: AngCN-SSG-S7 Version 1.0
2 CONTENTS Introduction...3 List of MDTs...3 Patients to be referred to the LSMDT...4 Patients to be referred to the SSMDT...4 Combined NNUHFT and Addenbrookes SMDT meetings...5 Appendices...6 Appendix 1: Rare skin tumours...6 Appendix 2: Levels of Care for Skin...7 Appendix 3: Indications for referral for Sentinel lymph node biopsy...8 Appendix 4: Indications for referral for Mohs surgery...9 Evidence of Agreement...10 Monitoring the Effectiveness of the Process...10 Page 2 of 10
3 Introduction The Anglia Cancer Network (AngCN) Skin Multidisciplinary Teams (MDTs) have been developed to deliver cancer services in accordance with the NICE Improving Outcomes Guidance for People with Skin Tumours including Melanoma (NICE 2006). The Anglia Cancer Network has: 8 Local Multidisciplinary Teams (LMDTs) These cover the secondary care of patients who are classed as care levels 2, 3 and 4 (please refer to appendix 2 for details of care levels for skin, as determined by NICE - Appendix 2: Levels of Care for Skin) 2 Specialist Multidisciplinary Teams (SMDTs) These cover the tertiary care of patients who are classed as care level 5. The two SMDTs make referrals to the Supra-Network MDT at St Thomas Hospital in London, and this supra-network MDT covers patients who are classed as care level 6 cutaneous lymphoma. In addition the two SMDTs combine as required to make joint care decisions for patients with rare skin cancers (Appendix 2). List of MDTs East LMDT (Secondary Care) Ipswich Hospital NHS Trust LMDT James Paget University Hospitals NHS Foundation Trust LMDT Queen Elizabeth Hospital NHS Trust, Kings Lynn, LMDT Norfolk and Norwich University Hospital NHS Foundation Trust LMDT SMDT (Tertiary Care) Norfolk and Norwich University Hospital NHS Foundation Trust SMDT West LMDT (Secondary Care) Addenbrooke s Hospital AND Hinchingbrooke Health Care NHS Trust (Joint) LMDT Bedford Hospital NHS Trust LMDT Peterborough & Stamford Hospitals NHS Foundation Trust LMDT West Suffolk Hospitals NHS Trust LMDT SMDT (Tertiary Care) Addenbrooke s Hospital SMDT Lead Clinician Sam Gibbs Robert Graham Gillian Dootson Jennifer Garioch Lead Clinician Jennifer Garioch Lead Clinician Pamela Todd (Melanoma) & Tom Ha (SCC) Katya Burova Richard (Dick) Mallett Sue Handfield-Jones Lead Clinician Pamela Todd Page 3 of 10
4 Joint Supra-Network MDT (Tertiary Care cutaneous lymphoma) St Thomas Hospital Lead Clinicians Sean Whittaker & Julia Scarisbrick Patients to be referred to the LSMDT All patients requiring level 3 or 4 care must be referred to a LSMDT (or to an SSMDT where it is acting as a local LSMDT). The following patients should be referred to the LSMDT. Low risk BCC incompletely or narrowly (< 1mm) excised, perineural invasion Low risk BCCs excised by non accredited GPs in the community High Risk BCC incompletely or narrowly ( < 1mm) excised, perineural invasion High risk BCCs excised by GPs in the community SCCs excised by GPs in the community SCC incompletely or narrowly excised (<1mm), perineural or lymphovascular invasion, thickness 6mm or more, pt2 or above, poorly differentiated tumours, specific histological subtypes (clear cell, desmoplastic, verrucous, carcinosarcoma, adenosquamous) SCCs from special or high risk sites (ear, lip, eyelid/canthus) Malignant melanoma new, single primary, adult, non-metastatic, not for approved trial entry, up to and incuding stage IIa Melanomas excised or biopsied in primary care Radiotherapy if attendance by clinical oncologist at LSMDT Lesion where diagnosis is uncertain but may be malignant Incompatible clinical and histological findings Patients to be referred to the SSMDT All patients requiring level 5 care should be referred to the SSMDT. In general, referral of cases will be made directly to the SSMDT. In certain circumstances, for example if the disease staging is upgraded, or if more specialist treatment such as Mohs microsurgery is deemed necessary, patients previously discussed at a LSMDT will then be referred on from the LSMDT to the SSMDT Those requiring level 5 care fall into a number of different skin tumour and patient groups. These are summarised below. Selected BCCs and SCCs needing plastic/reconstructive surgery by SMDT core member (as per network clinical guidelines) Radiotherapy (as per network clinical guidelines). If not discussed and treated by LMDT clinical oncology core team member Metastatic SCC on presentation or newly metastatic or recurrent. SCCs from special or high risk sites (perineum, sole of foot) MM stage Ib or more, or < 19 years or metastatic on presentation or newly Page 4 of 10
5 metastatic or recurrent or for approved trial entry or +ve excision margins Patients for sentinel lymph node biopsy (See Appendix 3: Indications for referral for Sentinel lymph node biopsy) Positive sentinel lymph node biopsies Patients with positive lymph nodes following lymph node clearance Any cases for adjuvant therapy (as per network clinical guidelines) Histology opinion from SMDT core pathology team member Mohs surgery (See Appendix 4: Indications for referral for Mohs surgery) Skin cancer in immunocompromised patients including organ transplant recipients Skin cancer in genetically predisposed patients including Gorlin s Syndrome Tumours associated with burns, albinism, xeroderma, post-irradiation Rare skin tumours sebaceous carcinoma, malignant pilomatrixoma, neuroendocrine carcinoma Cutaneous sarcoma superficial to the deep fascia Cutaneous lymphoma * Details of the SSMDTs are available in the Skin Operational Policy documents for Addenbrooke s and NNUHFT. * There are two cutaneous lymphoma MDTs within the Anglia Cancer Network. Details of these MDTs - including frequency, how to refer etc - are available in the Operational Policy Documents for Addenbrooke s and NNUHFT. Combined NNUHFT and Addenbrookes SMDT meetings The following diagnoses necessitate a joint Addenbrooke s and NNUHFT SSMDT: Children and young people with skin cancer Rare skin tumours as listed in the NICE IOG - except sebaceous carcinoma, malignant pilomatrixoma, neuroendocrine carcinoma - (Appendix 1: Rare skin tumours) See operational policy documents for process of referring to a joint Addenbrooke s and NNUHFT SSMDT. Page 5 of 10
6 Appendices Appendix 1: Rare skin tumours Epidermal and appendage tumours Apocrine carcinoma. Hidradenocarcinoma. Eccrine porocarcinoma. Sebaceous carcinoma. Tumours associated with Muir Torre syndrome. Eccrine epithelioma (syringoid carcinoma). Microcystic adnexal carcinoma. Primary adenoid cystic carcinoma. Primary mucoepidermoid carcinoma. Primary mucinous carcinoma. Digital papillary adenocarcinoma. Malignant cylindroma. Malignant spiradenoma (spiradenocarcinoma). Malignant pilar tumour. Malignant pilomatrixoma. Neuroendocrine carcinoma (Merkel cell tumour/trabecular carcinoma). Dermal and subcutaneous tumours Atypical fibroxanthoma (AFX) (superficial malignant fibrous histiocytoma, superficial sarcoma not otherwise specified). Dermatofibrosarcoma protuberans (DFSP). Leiomyosarcoma. Angiosarcoma. Kaposi s sarcoma. Haemangioendothelioma. Epithelioid sarcoma. Primary cutaneous rhabdomyosarcoma. Cutaneous malignant nerve sheath tumours (including cutaneous neurofibrosarcoma and malignant Schwannoma). Page 6 of 10
7 Appendix 2: Levels of Care for Skin Care Level Person or Team Case mix / Procedure 1 Any general practitioner in the community Benign lesions Actinic keratoses 2 General Practitioner with a Special Interest (GPwSIs) in Skin Cancer see Department of Health guidance i.e. model 1 in figure 2 3 LSMDT, hospital staff core team member (may be core member of SSMDT acting as local LSMDT). Without mandatory individual case review by MDT. 4 LSMDT, hospital staff core team member(s), with mandatory individual case review by LSMDT (may be the SSMDT and its core members acting as local LSMDT). 5 SSMDT hospital staff core team member(s) with mandatory individual case review by SSMDT. (May have been previously reviewed by LSMDT or rapidly referred without prior review). For some cases only one agreed SSMDT, if more than one in the network. Precancerous SCC, in situ/bowen s Low risk BCC High risk BCC SCC High risk BCC SCC Malignant melanoma new, single primary, adult, non-metastatic, not for approved trial entry, up to and incuding stage IIa (must fulfil all of these criteria) Radiotherapy if attendance by clinical oncologist at LSMDT Lesion where diagnosis is uncertain but may be malignant Incompatible clinical and histological findings Selected BCCs and SCCs needing plastic/reconstructive surgery by SMDT core member (as per network clinical guidelines) Radiotherapy (as per network clinical guidelines). If not discussed and treated by LMDT clinical oncology core team member Metastatic SCC on presentation or newly metastatic MM stage Ib or more, or < 19 years or metastatic on presentation or newly metastatic or recurrent or for approved trial entry or +ve excision margins Any cases for adjuvant therapy (as per network clinical guidelines) Histology opinion from SMDT core pathology team member Mohs surgery Skin cancer in immunocompromised patients including organ transplant recipients Skin cancer in genetically predisposed patients including Gorlin s Syndrome 6 Supranetwork team. Selected Networks only. Agreed with SCGs. Clinician responsible for named facilities for photopheresis (very small numbers of patients). Agreed with SCGs. Cases discussed in SSMDT for cutaneous lymphoma in host network. Cases to be dealt with by only one agreed SSMDT per Network, if more than one in the Network; Cutaneous lymphoma Kaposi s sarcoma Cutaneous sarcoma above superficial fascia. (Below fascia, refer to sarcoma MDT) in cancers Other rare skin cancers (see appendix 1 in the Skin Cancer IOG pg 128/129). T-cell Cutaneous Lymphoma: Total Body Surface Electron Beam Therapy. T-cell cutaneous lymphoma. Photopheresis. Page 7 of 10
8 Appendix 3: Indications for referral for Sentinel lymph node biopsy The following patients should be considered for sentinel lymph node biopsy: 1) All primary melanomas pt1b pt3b (a) All primary melanomas with Breslow thickness 1 to 4 mm. (b) Primary melanomas Breslow thickness mm. with any of the following: (i) (ii) (iii) Ulceration Mitotic rate >= 1 mitoses/mm² Age <40 years 2) All primary melanomas pt4+ (Breslow >4mm) AND age <=75 years 3) Melanomas of unknown Breslow thickness (usually curetted lesions) 4) Pigmented lesions of uncertain malignant potential 5) Merkel cell tumours The following patients would usually be excluded from sentinel lymph node biopsy: 1) Patients where the wider excision has already been performed 2) Recurrent or in transit disease 3) Patients assessed as unfit for a general anaesthetic 4) Patients with macroscopic stage III disease or evidence of stage IV disease Note: Patients older than 75 years of age should not be automatically referred for sentinel lymph node biopsy but should be discussed at the skin cancer multidisciplinary team meeting forum. Page 8 of 10
9 Appendix 4: Indications for referral for Mohs surgery Mohs surgery should be considered for patients with high risk basal cell carcinoma (BCC) - poorly defined BCC - incompletely excised BCC - histologically aggressive BCC (sclerosing or morphoeaform, infiltrating, perineural, perivascular, metatypical, keratinising, multicentric or those that involve deep tissue) - BCC at high risk sites: nose, periorbital area, ears - BCC arising in younger patients especially facial lesions - BCC arising from previously irradiated skin - BCC in immunocompromised patients - Where tissue sparing is important Other indications for Mohs surgery - Squamous cell carcinoma - Microcystic adnexal tumour - Sebaceous carcinoma - Atypical fibroxanthoma - Dermatofbrosarcoma protuberans Page 9 of 10
10 Evidence of Agreement This Guideline has been agreed by: The Anglia Cancer Network Board Name: Carole Taylor-Brown Position: Chief Executive Suffolk PCT and Chair of the Anglia Cancer Network Board Date agreed: 9 th June 2010 The SSG Members This document was agreed to at the Joint Skin SSG Meeting on 12 th May Monitoring the Effectiveness of the Process a) Process for Monitoring compliance and Effectiveness - Review of compliance as determined by audit. Any non compliance to be presented by QA Manager to the AngCN Business Meeting on an annual basis the minutes of this meeting are retained for a minimum of five years. b) Standards/Key Performance Indicators This process forms part of a quality system working to, but not accredited to, International Standard BS EN ISO 9001:2008. The effectiveness of the process will be monitored in accordance with the methods given in the quality manual, AngCN-QM Equality and Diversity Statement This document complies with the Suffolk PCT Equality and Diversity statement an EqIA assessment is available on request to Anglia Cancer Network QA Manager, Gibson Centre, Exning Road, Newmarket, CB8 7JG. Disclaimer It is your responsibility to check against the electronic library that this printed out copy is the most recent issue of this document. Please notify any changes required to the Anglia Cancer Network Quality Assurance Manager Page 10 of 10
Skin SSG (Anglia East & Anglia West)
Skin SSG (Anglia East & Anglia West) Author: Dr Jennifer Garioch, Consultant Dermatologist Dr Pamela Todd, Consultant Dermatologist Approved by: Anglia Cancer Network Skin NSSG Approved on: Reviewed and
More informationBrain and CNS tumours Presentation pathway
Brain and CNS tumours Presentation pathway Ref: AngCN-SSG-BC16 Page 1 of 8 1 Background and Scope This presentation pathway deals with the pathway of referral from all aspects of primary care to hospitals
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More informationChemotherapy Training and Assessment Policy. For Medical Prescribers and Pharmacy Verifiers
Chemotherapy Training and Assessment Policy For Medical Prescribers and Pharmacy Verifiers For approvals and version control see Document Management Record on page 6 Doc Ref: AngCN-CCG-C36 Approved and
More informationSkin SSG (Anglia East & Anglia West)
Guidelines for the Management of Skin Cancer in Specific Anatomical Sites Skin SSG (Anglia East & Anglia West) Author: Dr Jennifer Garioch, Consultant Dermatologist Dr Pamela Todd, Consultant Dermatologist
More informationGUIDELINES FOR THE MANAGEMENT OF
GUIDELINES FOR THE MANAGEMENT OF RENAL CANCER Date of endorsement: July 2011 Authors: Mr. RD Mills & Mr. WH Turner Ref: AngCN-SSG-U3 Page 1 of 14 Approved and Published: Aug 2011 Title: Guidelines for
More informationRef No: AngCN-SSG-Sa9. H:\Cancer Network\Tumour Site\Sarcoma\Peer Review\Active\AngCN-SSG- Sa9_v2_Anglia_Configuration_Sarcoma_Services.
Anglia Cancer Network Configuration of Sarcoma Services Please note this document has only been partially approved. For further details, approvals and version control please see Document Management Record
More informationGUIDELINES FOR THE MANAGEMENT OF BLADDER CANCER
GUIDELINES FOR THE MANAGEMENT OF BLADDER CANCER For approvals and version control see Document Management Record on page 9 Ref: AngCN-SSG-U4 Page 1 of 11 Approved and Published: Aug 2012 TABLE OF CONTENTS
More informationGuidance for the Network Review of Chemotherapy Errors
Guidance for the Network Review of Chemotherapy Errors For approvals and version control see Document Management Record on page 8 Doc Ref: AngCN-CCG-C31 Approved and published: March 2013 Page 1 of 8 Table
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Skin Cancer Network Site Specific Group. Clinical Guidelines.
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Skin Cancer Network Site Specific Group June 2017 Revision due: April 2019 Page 1 of 70 VERSION CONTROL THIS IS A CONTROLLED DOCUMENT.
More informationSquamous Cell Carcinoma. Basal Cell Carcinoma. Regional Follow-up Guidelines
West of Scotland Cancer Network Skin Cancer Managed Clinical Network Squamous Cell Carcinoma Basal Cell Carcinoma Regional Follow-up Guidelines Prepared by Dr M Porter, Dr A Matthews Approved by Skin Cancer
More informationAppendageal skin tumors
Appendageal skin tumors Ibrahim Khalifeh, M.D. Associate Professor Department of Pathology American University of Beirut Medical Center Beirut, Lebanon Appendageal tumors Neoplasms whose differentiation
More informationSlide seminar. Asist. Prof. Jože Pižem, MD, PhD Institute of Pathology Medical Faculty, University of Ljubljana
Slide seminar Asist. Prof. Jože Pižem, MD, PhD Institute of Pathology Medical Faculty, University of Ljubljana Case 5 A 57-year-old man with a dermal/subcutaneous lesion on the scalp, which was interpreted
More informationShared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1
Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Gynaecological sarcomas Version 1 Background This guidance is to provide direction for the management of patients with sarcomas
More informationAnnual Report Skin MDT
Annual Report Skin MDT University Hospitals Bristol NHS Foundation Trust 0117 923 0000 Minicom 0117 934 9869 www.uhbristol.nhs.uk Agreement and Approval Skin MDT Lead Clinician David DeBerker Date 29/08/2012
More informationCutaneous Adnexal Tumors
Cutaneous Adnexal Tumors Lesions with Predominant Follicular Differentiation Special Emphasis on Basal Cell Carcinoma 2014-04-01 Prof. Dr. med. Katharina Glatz Pathologie Cutaneous Adnexal Tumors Hair
More informationCutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.
Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma
More informationModalities of Radiation
Modalities of Radiation Superficial radiotherapy Orthovoltage Megavoltage Photons Electrons Brachytherapy Interstitial Moulds When to refer? The vast majority of skin cancers will be managed without any
More informationGuideline for the Management of Vulval Cancer
Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11
More informationVULVAR CARCINOMA. Page 1 of 5
VULVAR CARCINOMA EXAMPLE OF A VULVAR CARCINOMA USING PROPOSED TEMPLATE Case: Invasive squamous cell carcinoma arising in D-VIN Tumor in left labia major Left partial vaginectomy and sentinel lymph node
More informationDepartment of Dermatology, Queen Margaret & Victoria Hospitals
Department of Dermatology, Queen Margaret & Victoria Hospitals Management of primary skin cancer A copy of these local guidelines, national guidelines, information leaflets and other useful information
More informationWest Midlands Sarcoma Advisory Group
West Midlands Sarcoma Advisory Group Guideline for the Initial Investigation and Referral to Sarcoma Specialist Multi Disciplinary Team for Suspected Sarcoma of Soft Tissue Extremities (limbs and trunk
More informationGuidelines for the Management of Suspected Sarcoma in Primary Care
Guidelines for the Management of Suspected Sarcoma in Primary Care Author: Anglia Cancer Network Sarcoma SSG Document Approved Date: 16-Dec-10 Review Date: December 2012 Ref Code: AngCN-SSG-Sa1 Status:
More informationActivity Report March 2013 February 2014
West of Scotland Cancer Network Skin Cancer Managed Clinical Network Activity Report March 2013 February 2014 Dr Girish Gupta Consultant Dermatologist MCN Clinical Lead Tom Kane MCN Manager West of Scotland
More informationPATHOLOGY OF THE SKIN 2. Tumours of the skin
PATHOLOGY OF THE SKIN 2. Tumours of the skin Máirín E. McMenamin MB MRCPI FRCPath Dip (Dermatopathol) RCPath St. James s Hospital and University of Dublin, Trinity College Tumour (Neoplasia) Benign or
More informationBRITISH ASSOCIATION OF DERMATOLOGISTS WORKING PARTY REPORT ON SETTING STANDARDS FOR MOHS MICROGRAPHIC SURGERY SERVICES
BRITISH ASSOCIATION OF DERMATOLOGISTS WORKING PARTY REPORT ON SETTING STANDARDS FOR MOHS MICROGRAPHIC SURGERY SERVICES Recommendations of the British Society for Dermatological Surgery and British Association
More informationUpdate on Cutaneous Mesenchymal Tumors. Thomas Brenn
Update on Cutaneous Mesenchymal Tumors Thomas Brenn Cutaneous Mesenchymal Tumours Wide morphological and biological spectrum Myofibroblastic, smooth muscle, neural, vascular, apidocytic, undifferentiated;
More informationMalignant Melanoma Care Pathway
Malignant Melanoma Care Pathway Level 1-4 Community Skin Cancer Service Sussex Community Dermatology Service Version 3.0 Scope of Community Services for Malignant Melanoma All suspected cases of malignant
More informationCommon Benign Lesions and Skin Cancers. 22nd May 2015 Dr Mark Foley
Common Benign Lesions and Skin Cancers 22nd May 2015 Dr Mark Foley Thank you for downloading this file. This intended to supplement the presentation given at the NZ Wound Care Conference, it is not intended
More informationDermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial
Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial Cutaneous Oncology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI
More informationSection 1: Personal information
A survey on the use of ultrasound examination of the regional lymph nodes in the follow up of patients with high-risk cutaneous squamous cells carcinomas (SCCs). Note: In the definition of cutaneous squamous
More informationأملس عضلي غرن = Leiomyosarcoma. Leiomyosarcoma 1 / 5
Leiomyosarcoma 1 / 5 EPIDEMIOLOGY Exact incidence is unknown, but older studies suggest that leiomyosarcomas comprise approximately 3 percent of soft-tissue sarcomas. Superficial leiomyosarcoma occurs
More informationDavid B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma
Common Medicolegal Situations: Misdiagnosis of Melanoma David B. Troxel, MD Medical Director, The Doctors Company, Napa, California Clinical Professor Emeritus, University of California at Berkeley Past
More informationDRAFT SARCOMA MEASURES
Gateway 15612 Draft Sarcoma Measures Page 1 of 44 DH INFORMATION READER BOX Policy Estates HR / Workforce Commissioning Management IM & T Policy Planning / Finance Clinical Social Care / Partnership Working
More informationSKIN NSSG. (Lancs & South Cumbria) Constitution and Terms of Reference 2015
SKIN NSSG (Lancs & South Cumbria) Constitution and Terms of Reference 2015 VERSION : May 2015 1 The constitution has been agreed by: Position: Chair of Skin NSSG Name: Chris Dobson Organisation: Lancashire
More informationALASKA ARIZONA IDAHO MONTANA NORTH DAKOTA OREGON SOUTH DAKOTA UTAH WASHINGTON WYOMING
The following policy (L35704) has been archived by Alpha II. Many policies are part of a larger jurisdiction, than is indicated by the policy. This policy covers the following states: ALASKA ARIZONA IDAHO
More informationSkin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012
Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Case Presentation 57 yo man with 3 month hx of a nonhealing < 1 cm right
More informationAudit of plastic surgeons understanding of pathology reports of skin neoplasia
The British Association of Plastic Surgeons (2004) 57, 134 138 Audit of plastic surgeons understanding of pathology reports of skin neoplasia Y.S. Lau a, S.K. Suvarna b, *, L. Kangesu a, A. Mosahebi a
More informationBasal cell carcinoma 5/28/2011
Goal of this Presentation A practical approach to the diagnosis of cutaneous carcinomas and their mimics Thaddeus Mully, MD University of California San Francisco To review common non-melanoma skin cancers
More informationSkin Cancer of the Nose: Common and Uncommon
Skin Cancer of the Nose: Common and Uncommon Mark Russell, M.D. Associate Professor of Dermatology, Otolaryngology, and Pathology University of Virginia Objectives Review clinical presentations of select
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More informationUpdate on Sarcomas of the Head and Neck. Kevin Harrington
Update on Sarcomas of the Head and Neck Kevin Harrington Overview Classification and incidence of sarcomas Clinical presentation Challenges to treatment Management approaches Prognostic factors Radiation-induced
More informationSkin Cancer Pathway Board Constitution 2015
Skin Cancer Pathway Board Constitution 2015 _Web manchestercancer.org _Twitter @GM_Cancer _Email info@manchestercancer.org _Phone 0161 918 2087 Date f Date for Review: 2017_ Contents Measure number Measure
More informationAmerican College of Mohs Surgery. Diagnostic Quality Control Program (Review of Answers)
American College of Mohs Surgery Diagnostic Quality Control Program 2010 (Review of Answers) Question 1 A flesh-colored plaque on the right ala of an otherwise healthy 57 year-old male is referred for
More informationSKIN SERVICES REVIEW Changes to Medicare Benefits Schedule for 1 November 2016
Attachment A SKIN SERVICES REVIEW Changes to Medicare Benefits Schedule for 1 November 2016 Deleted items 31200-31215, 31230-31240 31255-31335 Colour Coding for new / updated items: MUCOSAL BIOPSY AND
More informationOCCG SERVICE SPECIFICATION (2017/18)
OCCG SERVICE SPECIFICATION (2017/18) Primary Care Service for Skin Cancers: Dermatology Shared Care Monitoring for Melanoma, Lichen Sclerosus and Squamos Cell Carcinoma 1. Background For patients who have
More informationMelanoma. Consultation on draft guideline - stakeholder comments. Comments to be submitted before 5pm on Friday 13 March 2015
Please note: Please fill in both the stakeholder organisation and name of commentator fields. We cannot accept forms with attachments such as research articles, letters or leaflets. Stakeholder organisation(s)
More informationWork Programme/Service Delivery Plan 2010/2013
Essex and East Suffolk Gynaecological Cancer Network Site Specific Group Work Programme/Service Delivery Plan 2010/2013 Version Number 1.2 Author Members of the NSSG Date Written June 2010 Reviewed May
More informationIT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY
IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY Skin, Bones, and other Private Parts Symposium Dermatology Lectures by Debra Shelby, PhD, DNP, FNP-BC, FADNP, FAANP Debra Shelby,
More informationBenign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc
1 Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc Benign lesions Seborrheic Keratoses: Warty, stuck-on Genetics and birthdays Can start in late
More informationHDR Brachytherapy for Skin Cancers. Joseph Lee, M.D., Ph.D. Radiation Oncology Associates Fairfax Hospital
HDR Brachytherapy for Skin Cancers Joseph Lee, M.D., Ph.D. Radiation Oncology Associates Fairfax Hospital No conflicts of interest Outline Case examples from Fairfax Hospital Understand radiation s mechanism
More informationINTERNAL VALIDATION REPORT...
INTERNAL VALIDATION REPORT... Network Trust Team AngCN CAMBRIDGE UNIVERSITY HOSPITALS Addenbrookes Sarcoma Locality Measures (11-1D-1l) - 2011/12 Date Self Assessment Completed 30th November 2011 Date
More informationJuly 2012 SKIN SURGERY SERVICE BRIEFING NOTES
SKIN SURGERY SERVICE BRIEFING NOTES Introduction The WBoP PHO has an agreement with the BoP District Health Board to deliver the Skin Surgery Service. The current period will expire on 30 June 2012 and
More informationProposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL
Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL on behalf of Dr Louise Lansbury, Prof Fiona Bath-Hextall Nottingham Centre for Evidence Based
More informationWest Yorkshire & Harrogate Cancer Alliance
West Yorkshire & Harrogate Cancer Alliance Guidelines for the Management of Skin Cancers Version 4 October 2017 Page 6 of 57 i Document Control Title Author(s) Owner Guidelines for the Management of skin
More informationCancer Reporting for Dermatologists. Florida Department of Health Florida Cancer Data System. March 9, Agenda
Cancer Reporting for Dermatologists Florida Department of Health Florida Cancer Data System March 9, 2011 Agenda Welcome Introductions Cancer Reporting in Florida BETA Participation Expectations Review
More informationSouth East England General Histopathology EQA Scheme
South East England General Round a Final Case Analyses Cases 635 to 646 Circulated January February 2016 131 responses (89.73%) Prepared April 2016 Authorised by: Prof J Schofield Date: 19/4/2016 With
More informationColorectal NSSG. Constitution
Colorectal NSSG Constitution For approvals and version control see Document Management Record on page 10 Ref No: AngCN-SSG-C7 Page 1 of 10 Table of Contents 1 Membership of the Colorectal NSSG (1A-201d)...3
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Skin Cancer Network Site Specific Group. Constitution.
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Skin Cancer Network Site Specific Group Constitution June 2015 Revision due: April 2016 Page 1 of 31 VERSION CONTROL THIS IS A CONTROLLED
More informationDISORDERS OF THE SALIVARY GLANDS Neoplasms Dr.M.Baskaran Selvapathy S IV
DISORDERS OF THE SALIVARY GLANDS Neoplasms Dr.M.Baskaran Selvapathy S IV NEOPLASMS A) Epithelial I. Benign Pleomorphic adenoma( Mixed tumour) Adenolymphoma (Warthin s tumour) Oxyphil adenoma (Oncocytoma)
More informationCarcinoma of the Skin
Carcinoma of the Skin Protocol applies to invasive carcinomas of the skin, excluding eyelid, vulva, and penis. Excludes melanoma, sarcoma, and hematopoietic malignancy. Procedures Biopsy (No Accompanying
More informationSKIN CANCER. Most common cancer diagnosis 40% of all cancers
SKIN CANCER Most common cancer diagnosis 40% of all cancers OBJECTIVES Review common and uncommon cancers of the skin. Special emphasis on melanoma and dysplastic nevus Review pathology/tnm/staging, which
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationWest Midlands Sarcoma Advisory Group
West Midlands Sarcoma Advisory Group Guideline for the Initial Investigation and Referral to Specialist Sarcoma Multi Disciplinary Team for Suspected Bone Sarcoma Version History Version Date Brief Summary
More informationJournal of International Academy of Forensic Science & Pathology (JIAFP)
Journal of International Academy of Forensic Science & Pathology (JIAFP) ISSN 2395-0722 MICROCYSTIC ADNEXAL CARCINOMA-A CASE REPORT WITH REVIEW OF LITERATURE Case Report Sulakshana M S 1,Natarajan M 2
More informationDa Costa was the first to coin the term. Marjolin s Ulcer: A Case Report and Literature Review. Case Report. Introduction
E-Da Medical Journal 2016;3(2):24-28 Case Report Marjolin s Ulcer: A Case Report and Literature Review Yue-Chiu Su 1, Li-Ren Chang 2 Marjolin s ulcer is an aggressive cutaneous malignancy, which is common
More information- Selected Tumors of the Skin Appendages - Primary vs. Metastasis
- Selected Tumors of the Skin Appendages - Primary vs. Metastasis Napa Valley 2018 Victor G. Prieto, MD, PhD Chair of Pathology UT MD Anderson Cancer Center vprieto@mdanderson.org Napa Valley in May Introduction
More informationSkin Cancer Clinical Network Group (CNG)
Skin Cancer Clinical Network Group (CNG) Constitution 2014-2015 Version 1.0 This Constitution has been agreed by: Title Name Date Agreed Skin Cancer CNG Co-Chair Skin Cancer CNG Co-Chair Andrea Howes Philip
More informationHistory A 89 year old gentleman presenting with a scalp/forehead nodule. Patient had squamous cell carcinoma 18 m at same site, excised. Outside diagn
Case III History A 89 year old gentleman presenting with a scalp/forehead nodule. Patient had squamous cell carcinoma 18 m at same site, excised. Outside diagnoses: Squamous cell carcinoma. R/O: SCC, Melanoma,
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Assistant Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationSkin Cancer as a Contraindication to Organ Transplantation
American Journal of Transplantation 2005; 5: 2079 2084 Blackwell Munksgaard Minireview Copyright C Blackwell Munksgaard 2005 doi: 10.1111/j.1600-6143.2005.01036.x Skin Cancer as a Contraindication to Organ
More informationUpper GI Cancer Network Site-Specific Group. Work Programme/Service Delivery Plan 2011/14
Upper GI Cancer Network Site-Specific Group Work Programme/Service Delivery Plan 2011/14 1 UPPER GI NSSG Work Programme/Service Delivery Plan AGREEMENT COVER SHEET 2011/14 This Work Programme has been
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationGuideline for the Management of Patients Suitable for Immediate Breast Reconstruction
Version History Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction Version Summary of change Date Issued 2.0 Endorsed by the Governance Committee 20.02.08 2.1 Circulated
More informationMelanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG
Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationYou Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018
You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:
More informationTechnicians & Nurses Program
ASCRS ASOA Symposium & Congress Technicians & Nurses Program May 6-10, 2016 New Orleans Evaluation and Treatment of Eyelid Malignancies Richard C. Allen MD PhD FACS Professor Section of Ophthalmology Dept.
More informationI have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee
I have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee Some thoughts Is this skin cancer? How common is this? How likely is this in this patient? What happens next if it s something
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationSkin Cancer in Organ Transplant Recipients Challenges and Opportunities
Disclosure Skin Cancer in Organ Transplant Recipients Challenges and Opportunities Investigator: DUSA Pharmaceuticals, Inc. Investigator: Genentech Consultant: Gerson Lehrman Group Sarah Tuttleton Arron,
More informationNonmelanoma skin cancers
Skin cancer Philip Clarke Nonmelanoma skin cancers Treatment options Background Australia has one of the highest skin cancer rates in the world. Early detection and treatment of skin cancer is vital to
More informationCURRENT ISSUES IN TRANSPLANT DERMATOLOGY
CURRENT ISSUES IN TRANSPLANT DERMATOLOGY NO CONFLICTS OF INTEREST TO DISCLOSE SOLID ORGAN TRANSPLANTATION: 2015 As of April 10, 2015.. 123,319 patients waiting for an organ transplant 2,557 performed this
More informationFaster Cancer Treatment Indicators: Use cases
Faster Cancer Treatment Indicators: Use cases 2014 Date: October 2014 Version: Owner: Status: v01 Ministry of Health Cancer Services Final Citation: Ministry of Health. 2014. Faster Cancer Treatment Indicators:
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationContrast with Australian Guidelines A/Pr Pascale Guitera,
Contrast with Australian Guidelines A/Pr Pascale Guitera, Dermatologist, Sydney University NO CONFLICT OF INTEREST Sydney Melanoma Diagnostic Centre, RPAH 2011 2008 225 pages 16 pages http://www.cancer.org.au/file/healthprofessionals/clinica
More informationGlenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine
Glenn D. Goldman, MD Fletcher Allen Health Care University of Vermont College of Medicine Recognize and identify the main types of skin cancer Understand how and why Mohs surgery is utilized for the treatment
More informationNational Breast Cancer Audit next steps. Martin Lee
National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast
More informationIdentifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018
Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma
More information5/20/2015. Mohs Surgery BCCA High risk anatomic locations. Mohs Surgery High risk anatomic locations. Mohs Surgery Histologically Aggressive BCCA
Mohs Surgery BCCA High risk anatomic locations High risk areas H zone nasal ala, nasal septum, nasal ala groove, periorbital region, periauricual region, region around and in ear canal, ear pinna and scalp
More informationCranium eroding sweat gland carcinoma: a case report
Cranium eroding sweat gland carcinoma: a case report Mehmet Arslan, Ahmet N. Karadeniz, Görkem Aksu, Murat Güveli Istanbul University, Institute of Oncology, Istanbul, Turkey Background. Sweat gland carcinomas
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationGuidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationThis protocol is intended to assist pathologists in providing
Protocol for the Examination of Specimens From Patients With Carcinomas of the Skin, Excluding Eyelid, Vulva, and Penis* A Basis for Checklists Mark R. Wick, MD; Carolyn Compton, MD, PhD; for the Members
More informationSoft Tissue Tumour & Sarcoma Imaging Guidelines 2012
Soft Tissue Tumour & Sarcoma Imaging Guidelines 2012 Version Control This is a controlled document please destroy all previous versions on receipt of a new version. Date Approved: March 2011 reissued April
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationPanel consensus was not to include suggested revision.
DFSP-2 Footnote f should be revised to more accurately reflect current practice and the supporting literature and should read, 5,000-6,600 cgy for close-to-positive or positive margins (200 cgy fractions
More information